| Omega Therapeutics Lands $85M to Tap Into “Control Room” of Biology | Frank Vinluan | 07/29/20 | Boston |
| Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More | Sarah de Crescenzo | 06/12/20 | National |
| Forma Therapeutics Eyes IPO to Advance Sickle Cell, Prostate Cancer Drugs | Sarah de Crescenzo | 05/29/20 | Boston |
| With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future? | Ben Fidler | 08/08/18 | San Francisco |
| Bio Roundup: Big Bucks For Calico, Data Dumps & The IPO Wave Rolls On | Ben Fidler | 06/29/18 | National |
| With $59M, Casma and Ex-Constellation CEO Take Aim at Cellular Trash | Ben Fidler | 05/03/18 | Boston |
| Bio Roundup: Lung Cancer Showdown, Gene Therapy Deals, IPO Busts | Ben Fidler | 04/13/18 | National |
| Bio Roundup: Skinny Cuts, Genomic Approvals, Unfrozen FDA & More | Alex Lash | 05/26/17 | National |
| Constellation Reboots With Eye On Immuno-Oncology, Hires New CEO | David Holley | 05/25/17 | Boston |
| Bio Roundup: CAR-T & Migraine Races, Intra-Cellular, Rockefeller & More | Ben Fidler | 09/30/16 | National |
| Constellation Pharmaceuticals Lands $24,298,209 New Financing Round | VentureDeal | 09/28/16 | Boston |
| Celgene Passes on Acetylon as Another Option-to-Buy Deal Flames Out | Ben Fidler | 08/08/16 | Boston |
| East Coast Biotech Roundup: ASH, Kallyope, SQZ, Kyras & More | Ben Fidler | 12/11/15 | Boston |
| Constellation Pharmaceuticals Lands $55,000,000 New Funding Round | VentureDeal | 12/10/15 | Boston |
| With Drugs in Clinic, Constellation Nabs $55M For IPO Push | Alex Lash | 12/09/15 | Boston |
| East Coast Biotech Roundup: StartUp Health, Constellation, Highline & More | Ben Fidler | 08/28/15 | New York |
| Constellation Pharma Plots IPO Run As Genentech Passes on Buyout Deal | Ben Fidler | 08/24/15 | Boston |
| East Coast Biotech Roundup: Alnylam, Stock Offerings, Curis, & More | Ben Fidler | 01/23/15 | Boston |
| Constellation Pharmaceuticals Garners $5,000,000 New Financing | VentureDeal | 08/05/14 | Boston |
| David Schenkein, Cancer Doc Turned CEO, Aims to Build New Genentech | Ben Fidler | 10/16/13 | Boston |
| East Coast Life Sciences Roundup: Genocea, Biogen, OvaScience, & More | Ben Fidler | 09/13/13 | Boston |
| Epizyme Prices IPO at $15 Per Share, Begins Trading Friday | Ben Fidler | 05/30/13 | Boston |
| Meet Ben Fidler, Xconomy’s New East Coast Biotech Editor | Luke Timmerman | 04/15/13 | New York |
| Third Rock Stocks Up With $516M New Fund, Looks to Start 16 Cos | Luke Timmerman | 03/25/13 | Boston |
| Third Rock’s Bet on Lotus Tissue Repair Generates Big Return | Luke Timmerman | 02/27/13 | Boston |
| See the Agenda for ‘Reinventing Biotech’s Business Model’ Oct. 16 in SF | Luke Timmerman | 10/10/12 | San Francisco |
| See What GSK, J&J, KPCB, Third Rock & Orbimed Have in Common Oct. 16 | Luke Timmerman | 10/03/12 | San Francisco |
| Boston Scientific, Foundation, GnuBio, & More in Boston Life Sciences News | Erin Kutz | 09/21/12 | Boston |
| Seventh Sense, Polaris, & More Boston Life Sciences Newsmakers | Erin Kutz | 06/15/12 | Boston |
| Global Blood Therapeutics, Third Rock’s First West Coast Startup, Gets $41M | Luke Timmerman | 06/14/12 | San Francisco |
